Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 I291_Y308del |
Therapy | Pemigatinib |
Indication/Tumor Type | cholangiocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 I291_Y308del | cholangiocarcinoma | predicted - sensitive | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-207), Pemazyre (pemigatinib) treatment demonstrated safety in previously treated patients with advanced solid tumors harboring an activating non-kinase domain mutation in FGFR1, FGFR2, or FGFR3, and resulted in an objective response rate of 9.4% (3/32, partial responses), including a partial response with a progression-free survival of 14.8 months in a patient with cholangiocarcinoma harboring FGFR2 I291_Y308del (PMID: 38710951; NCT03822117). | 38710951 |
PubMed Id | Reference Title | Details |
---|---|---|
(38710951) | Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. | Full reference... |